<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Evid Based Complement Alternat Med</journal-id><journal-id journal-id-type="iso-abbrev">Evid Based Complement Alternat Med</journal-id><journal-id journal-id-type="publisher-id">ECAM</journal-id><journal-title-group><journal-title>Evidence-based Complementary and Alternative Medicine : eCAM</journal-title></journal-title-group><issn pub-type="ppub">1741-427X</issn><issn pub-type="epub">1741-4288</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23606875</article-id><article-id pub-id-type="pmc">3623263</article-id><article-id pub-id-type="doi">10.1155/2013/263805</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Effect of GutGard in the Management of <italic>Helicobacter pylori</italic>: A Randomized Double Blind Placebo Controlled Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Puram</surname><given-names>Sreenivasulu</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Suh</surname><given-names>Hyung Chae</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Seung Un</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Bethapudi</surname><given-names>Bharathi</given-names></name><xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Joseph</surname><given-names>Joshua Allan</given-names></name><xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Agarwal</surname><given-names>Amit</given-names></name><xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kudiganti</surname><given-names>Venkateswarlu</given-names></name><xref ref-type="aff" rid="I5">
<sup>5</sup>
</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>D2L Pharma Research Centre, Bangalore 560 037, India</aff><aff id="I2"><sup>2</sup>NICS, Seoul 135-763, Republic of Korea</aff><aff id="I3"><sup>3</sup>Korea Polytechnic University, Siheung-Si 429-793, Republic of Korea</aff><aff id="I4"><sup>4</sup>Research and Development Centre, Natural Remedies, Plot No.5B, Veerasandra Indl. Area, 19th K.M. Stone, Hosur Road, Electronic City, Bangalore, Karnataka 560 100, India</aff><aff id="I5"><sup>5</sup>Anasuya Ayurveda Centre, Bangalore 560 050, India</aff><author-notes><corresp id="cor1">*Joshua Allan Joseph: <email>joshua@naturalremedy.com</email></corresp><fn fn-type="other"><p>Academic Editor: Byung-Cheul Shin</p></fn></author-notes><pub-date pub-type="ppub"><year>2013</year></pub-date><pub-date pub-type="epub"><day>27</day><month>3</month><year>2013</year></pub-date><volume>2013</volume><elocation-id>263805</elocation-id><history><date date-type="received"><day>3</day><month>12</month><year>2012</year></date><date date-type="rev-recd"><day>11</day><month>2</month><year>2013</year></date><date date-type="accepted"><day>11</day><month>2</month><year>2013</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2013 Sreenivasulu Puram et al.</copyright-statement><copyright-year>2013</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>A randomized, double blind placebo controlled study was conducted to evaluate the efficacy of GutGard (root extract of <italic>Glycyrrhiza glabra</italic>) in the management of <italic>Helicobacter pylori</italic> (<italic>H. pylori</italic>) gastric load. Participants diagnosed with <italic>H. pylori</italic> infection were randomly assigned to two groups to orally receive 150&#x02009;mg of GutGard (<italic>n</italic> = 55) or placebo (<italic>n</italic> = 52) once daily for 60 days. <italic>H. pylori</italic> infection was assessed using <sup>13</sup>C-urea breath test (<sup>13</sup>C-UBT) at days 0, 30, and 60. Stool Antigen test (HpSA) was also performed on days 0, 30, and 60. Repeated measures of analysis of variance (RMANOVA), chi-square, and Fisher's exact probability tests were used to compare the treatment outcomes. A significant interaction effect between group and time (<italic>P</italic> = 0.00) and significant difference in mean Delta Over Baseline (DOB) values between GutGard (<italic>n</italic> = 50) and placebo (<italic>n</italic> = 50) treated groups after intervention period were observed. On day 60, the results of HpSA test were negative in 28 subjects (56%) in GutGard treated group whereas in placebo treated group only 2 subjects (4%) showed negative response; the difference between the groups was statistically significant. On day 60, the results of <sup>13</sup>C-UBT were negative in 24 (48%) in GutGard treated group and the difference between the groups was statistically significant. The findings suggest GutGard is effective in the management of <italic>H. pylori</italic>.</p></abstract></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>
<italic>Helicobacter pylori</italic> (<italic>H. pylori</italic>) is a gram-negative spiral, or helical shaped bacteria inhabiting the gastric epithelial cells [<xref rid="B1" ref-type="bibr">1</xref>], of half the world human population, with prevalence rates reported to be highly variable in different regions of the industrialized and developing countries ranging from nearly 7% to greater than 95% [<xref rid="B2" ref-type="bibr">2</xref>]. Presence of <italic>H. pylori </italic>is associated with an increased risk of developing upper gastrointestinal tract diseases, namely, peptic ulcer disease [<xref rid="B3" ref-type="bibr">3</xref>&#x02013;<xref rid="B5" ref-type="bibr">5</xref>], gastric carcinoma [<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>], and gastric MALT lymphoma. Also, World Health Organization classified <italic>H. pylori</italic> as a type I carcinogen for gastric carcinoma [<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>].</p><p>Maastricht III Consensus and American College of Gastroenterology recommended standard triple therapy (a proton pump inhibitor (PPI), clarithromycin, and amoxicillin/or metronidazole) and Bismuth-based quadruple therapy (Bismuth with PPI and two antibiotics) as first line treatments in subjects infected with <italic>H. pylori</italic> [<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>]. However, the success rates of these therapies have not been very encouraging. Despite the large number of studies, identifying an optimal regimen for <italic>H. pylori,</italic> treatment still remains a challenging clinical problem. The primary cause for failure reported in systematic review and meta-analysis reports is <italic>H. pylori</italic> resistance to the antibiotics [<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>]. Although use of molecular test systems can detect the resistance, this does not provide long term solution to rising tendency of resistance to antibiotics [<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>]. Besides resistance, adverse effects and poor patient compliance limit the efficacy of these regimens. Considering the limitations in treatment regimens, development of alternative remedies remains constant need. With the growing popularity for naturally occurring medicinal plants, herbal preparations have been evaluated for the management of <italic>H. pylori </italic>and one such medicinal plant that holds promise for <italic>H. pylori</italic> management is licorice [<xref rid="B16" ref-type="bibr">16</xref>]. Licorice (<italic>Glycyrrhiza glabra</italic> Linn; Family: Leguminosae) has been in traditional use for several centuries. The roots and rhizomes of <italic>G. glabra</italic> have been reported for antipyretic, antimicrobial, hepatoprotective, antioxidant, antiadhesive, anxiolytic, expectorant, laxative, and diuretic properties [<xref rid="B17" ref-type="bibr">17</xref>&#x02013;<xref rid="B20" ref-type="bibr">20</xref>]. In addition <italic>G. glabra</italic> has antiviral, antiinflammatory, anticancer, anti-ulcer activities [<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B22" ref-type="bibr">22</xref>].</p><p>
<italic>G. glabra</italic> was reported to exhibit antimicrobial activity against several gram-negative and gram-positive bacterial strains including <italic>H. pylori</italic> [<xref rid="B23" ref-type="bibr">23</xref>]. Besides these, licorice also demonstrated beneficial effects on <italic>H. pylori</italic> through its antiadhesive properties [<xref rid="B20" ref-type="bibr">20</xref>]. Activity against ulcer and cancer, clinical outcomes of <italic>H. pylori</italic> infection were also exhibited by licorice. Curative effect of deglycyrrhizinated licorice (DGL) on ulcer has been reported <italic>in vivo</italic> and in clinical studies [<xref rid="B24" ref-type="bibr">24</xref>&#x02013;<xref rid="B26" ref-type="bibr">26</xref>], whereas, anti-cancer effect of licorice extract was established in <italic>in vitro</italic> study [<xref rid="B27" ref-type="bibr">27</xref>].</p><p>GutGard is a deglycyrrhizinated root extract of <italic>G. glabra</italic>, the safety and efficacy of which was evaluated in several studies conducted earlier. <italic>In vitro</italic> battery of genotoxicity tests showed no evidence of clastogenic and mutagenic effects and in acute oral toxicity study GutGard was found to be safe up to 5000&#x02009;mg/kg rat body weight [<xref rid="B28" ref-type="bibr">28</xref>]. A randomized, double-blind, placebo-controlled clinical study reported significant decrease in symptoms scores of functional dyspepsia and also did not report any major trial related adverse effects [<xref rid="B29" ref-type="bibr">29</xref>]. Furthermore, GutGard exhibited anti-inflammatory activity likely through inhibition of COX and LOX pathways [<xref rid="B28" ref-type="bibr">28</xref>] and anti-ulcer activity was demonstrated in pylorus ligation, cold-restraint stress, and indomethacin induced ulcer in albino Wistar rats in which at 12.5, 25, and 50&#x02009;mg/kg dose levels, the effects were found in dose dependent manner [<xref rid="B30" ref-type="bibr">30</xref>]. </p><p>From the above considerations <italic>G. glabra</italic> is found to have potential activity against gastrointestinal related disorders and this study in particular was aimed to assess the efficacy of GutGard, in the management of <italic>H. pylori </italic>in a randomized double blind placebo controlled trial.</p></sec><sec id="sec2"><title>2. Methods</title><sec id="sec2.1"><title>2.1. Subjects</title><p>Subjects, aged between 18&#x02013;45 years with positive response in <italic>H. pylori</italic> stool antigen test (HpSA) and <sup>13</sup>C-urea breath test (<sup>13</sup>C-UBT), were enrolled. Subjects were excluded if they (i) had history of bleeding duodenal ulcer, MALT lymphoma, gastroesophageal reflux, surgery for ulcers; (ii) had advanced chronic illness, mental illness, dementia, or suffering with concomitant symptoms of the irritable bowel syndrome, (iii) were first level relatives to gastric cancer patients, (iv) were taking antibiotics and/or PPIs and/or H 2 -antagonists 2 weeks prior to the administration of the investigational product and were using nonsteroidal anti-inflammatory drugs, steroids, bismuth preparation, (v) were participating in other clinical trials, (vi) were pregnant/lactating, (vii) were engaged in drug or alcohol abuse.</p></sec><sec id="sec2.2"><title>2.2. Study Intervention</title><p>Each capsule of GutGard contains 150&#x02009;mg of actives of <italic>G. glabra</italic>. GutGard is a flavonoid rich, root extract of <italic>G. glabra</italic> developed by Natural Remedies, Bangalore, India. GutGard has the following phytochemical specifications, namely, glabridin (&#x02265;3.5%&#x02009;w/w), glabrol (&#x02265;0.5%&#x02009;w/w), eicosanyl caffeate (&#x02265;0.1%&#x02009;w/w), docosyl caffeate (&#x02265;0.1%&#x02009;w/w), glycyrrhizin (&#x02264;0.5%&#x02009;w/w), and total flavonoids (&#x02265;10%&#x02009;w/w). </p></sec><sec id="sec2.3"><title>2.3. Study Protocol</title><p>The double blind placebo controlled trial was conducted in D2L Pharma Research Centre, Bangalore, Karnataka, India, from July 2011 to November 2011. Ethics Committee approval was obtained for the conduct of the trial. A total of 215 subjects were screened and 107 subjects with positive response to HpSA test and <sup>13</sup>C-UBT were recruited. The investigator clearly explained the purpose and methodology of the clinical trial in a simple, explicable language before taking consent from the subjects for participation in the trial. In addition the queries/doubts of trial subjects if any were clarified by the investigator prior to signing the consent form. The subjects were asked to completely understand and sign the informed consent form. The subjects were informed that they can withdraw from the study at any point without any prior notice. It was informed, if the subject volunteers to provide the reasons for opting out, consent to use this information will be taken from the subject. Following the consent, the subjects were randomly assigned to GutGard (<italic>n</italic> = 55) and placebo (<italic>n</italic> = 52) groups. A computer aided programme was used to generate randomization list and the random numbers were considered as subject code. As per the random allocation sequence, the containers (either GutGard or placebo) were labeled with unique random numbers. The entire process was carried out in a confidential manner and all the study related personnel, namely, investigators, subjects, and other supportive staff were unaware of the random allocation sequence. </p><p>The study medication was dispensed by the pharmacist to the subjects taking into consideration the order of enrollment and as per the random allocation sequence. Both GutGard and placebo capsules were similar in appearance (size, shape, and color) and flavor including packaging. The study interventions were packaged and labeled identically to maintain blinding. The personnel (investigator, pharmacist, and subjects) involved in the trial were blinded during the trial period. Each subject was given a container of 30 capsules and was advised to take one capsule daily with a glass of water before food in the morning for 30 days. The subjects were informed to visit the trial centre on day 30 along with the container and the study diary card. The compliance to study medication was recorded by counting the leftover capsules in the container and from the diary card. After recording the compliance, another container of 30 capsules was provided to the subjects and the same procedure was followed at the scheduled followup on day 60.</p></sec><sec id="sec2.4"><title>2.4. Outcome Measures</title><p>The gastric load of <italic>H. pylori</italic> was assessed on days 0, 30, and 60. Decrease in <italic>H. pylori</italic> gastric load was assessed using <sup>13</sup>C-UBT and HpSA test as outcome measures. The proportion of subjects with initial positive <sup>13</sup>C-UBT and HpSA test results found to be negative at day 30 and day 60 was measured. </p></sec><sec id="sec2.5"><title>2.5. Data Analysis</title><p>The required sample size for the GutGard clinical study in the management of <italic>H. pylori</italic> was calculated using the formula <italic>n</italic> = (8(<italic>CV</italic>)<sup>2</sup>/(PC)<sup>2</sup>)(1 + (1 &#x02212; PC)<sup>2</sup>) [<xref rid="B31" ref-type="bibr">31</xref>] where proportionate change in means (PC) of 20% [<xref rid="B32" ref-type="bibr">32</xref>] with 35% of coefficient of variation (<italic>CV</italic>) was considered. Assuming a possibility of lost to followup or dropouts as 20% at least 50 subjects were needed for each group. Hence, the required sample size was calculated as 100 subjects for the entire study. </p><p>At baseline, the characteristics of the subjects of the two groups were compared by independent sample <italic>t</italic>-test. The cure rates and the interaction effects between group and time were determined using per protocol (PP) analysis. The Delta Over Baseline (DOB) values were expressed as mean &#x000b1; SD at days 0, 30, and 60 and were analyzed by repeated measures of analysis of variance (RMANOVA) and the statistical significance was set at <italic>P</italic> &#x02264; 0.05. Positive and negative responses from the HpSA test and <sup>13</sup>C-UBT were assessed. The proportion of individuals showing positive and negative response to <sup>13</sup>C-UBT in GutGard and placebo treated groups was analyzed using Fisher's exact probability test, and chi-square test was used to analyze the proportion of individuals showing positive and negative response to HpSA test. The statistical analysis of side effects was performed with the chi-square analysis. </p></sec></sec><sec id="sec3"><title>3. Results</title><p>A total of 215 subjects were screened initially, and 107 subjects were recruited. Seven out of the 107 enrolled were excluded from the study as they did not satisfy the inclusion criteria for age (subjects were over 45 years of age); finally, 100 subjects per protocol were analyzed (<xref ref-type="fig" rid="fig1">Figure 1</xref>). At baseline mean characteristics of treated group versus placebo were found to be comparable (<xref ref-type="table" rid="tab1">Table 1</xref>). A significant interaction effect between group and time (df = 2,196; <italic>F</italic> = 1120.27; <italic>P</italic> = 0.00) and time effect was observed between the groups. Significant difference in mean DOB values was observed between GutGard and placebo treated groups after intervention period. The magnitude of decrease in the <italic>H. pylori</italic> load is summarized in <xref ref-type="table" rid="tab2">Table 2</xref>. The proportion of subjects turned from positive to negative response status is elucidated in <xref ref-type="table" rid="tab3">Table 3</xref>. At day 0 and day 30 all the subjects in placebo and GutGard treated groups showed positive response to HpSA test and <sup>13</sup>C-UBT. On day 60, the results of HpSA test were negative in 28 subjects (56%) in GutGard treated group and 2 subjects (4%) in placebo treated group; the difference between the groups was statistically significant. On day 60, the results of <sup>13</sup>C-UBT were negative in 24 (48%) in GutGard and one (2%) in placebo consumed subjects; the difference was statistically significant. </p><p>
<italic>Safety</italic>. Regarding the overall tolerability of interventions, in total 22 subjects (22%) showed at least one side-effect. One subject (1%) experienced moderate side-effect (fever); 21 subjects (21%) experienced mild side-effects, but none stopped the treatment and all have completed the study. The incidences of side-effects were considered to be not related to treatment. The profiles and frequencies of side-effects were listed in <xref ref-type="table" rid="tab4">Table 4</xref>. On comparison, the frequencies of side-effects between GutGard and placebo treated groups were non-significant (<xref ref-type="table" rid="tab4">Table 4</xref>).</p></sec><sec id="sec4"><title>4. Discussion</title><p>Extensive research in the past few decades since the discovery of <italic>H. pylori</italic> indicated that it is the major risk factor for gastrointestinal disorders and the research guidelines recommended that all <italic>H. pylori</italic> positive individuals be treated irrespective of the clinical outcome. The eradication of <italic>H. pylori </italic> in the infected subjects will not only prevent <italic>H. pylori </italic> associated diseases but also limit the spread of infection [<xref rid="B33" ref-type="bibr">33</xref>]. Albeit, different regimens are available for the treatment of <italic>H. pylori</italic>, the success rates of these regimens are low due to the rising prevalence of antimicrobial resistance and an effective regimen for <italic>H. pylori</italic> still remains elusive. Use of herbal supplements as alternative sources has attracted the researchers worldwide over the past few years and several studies on medicinal plants have been undertaken to evaluate the anti-<italic>H. pylori</italic> effects [<xref rid="B34" ref-type="bibr">34</xref>&#x02013;<xref rid="B37" ref-type="bibr">37</xref>]. From the published preclinical studies, <italic>G. glabra</italic> is reported to possess activity against <italic>H. pylori</italic> [<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B39" ref-type="bibr">39</xref>]; however, the major concern is the validation of these effects in well designed clinical settings. In the present study, GutGard, an extract of <italic>G. glabra</italic>, has been evaluated in a double blind placebo controlled trial for its efficacy in the management of <italic>H. pylori</italic> representing one of the pioneering studies in this aspect.</p><p>In the present study, effectiveness of GutGard supplementation for 60 days was evaluated in subjects positive for <italic>H. pylori</italic> based on the HpSA and <sup>13</sup>C-UBT results pre- and posttreatment. An interaction effect with significant difference in mean DOB values between GutGard and placebo treated groups after intervention period was observed. DOB is increasingly recognized as a quantitative measure of <italic>H. pylori </italic> gastric load [<xref rid="B40" ref-type="bibr">40</xref>]. The bacterial urease activity, which correlates with DOB values, mainly depends on the overall bacterial load [<xref rid="B41" ref-type="bibr">41</xref>] and some studies have suggested that high DOB values are associated with a high bacterial load in the stomach [<xref rid="B42" ref-type="bibr">42</xref>&#x02013;<xref rid="B44" ref-type="bibr">44</xref>] as well as with <italic>H. pylori</italic> virulence factors, such as CagA [<xref rid="B45" ref-type="bibr">45</xref>, <xref rid="B46" ref-type="bibr">46</xref>]. The data on GutGard indicates that the <italic>H. pylori</italic> load was significantly decreased in GutGard treated subjects as compared to placebo treatment. Apart from decrease in gastric load of <italic>H. pylori</italic>, the GutGard treated subjects showed negative response in <sup>13</sup>C-UBT and tested negative in HpSA test. The results of HpSA and <sup>13</sup>C-UBT in terms of number of subjects with negative <italic>H. pylori </italic> test findings are in concordance with earlier study outcomes which demonstrated that <sup>13</sup>C-UBT and HpSA are absolutely equivalent in terms of sensitivity and specificity in the evaluation of eradication therapy [<xref rid="B47" ref-type="bibr">47</xref>&#x02013;<xref rid="B49" ref-type="bibr">49</xref>].</p><p>Several studies have evaluated the effects of supplementation of extracts of medicinal herbs along with standard treatment regimens in the management of <italic>H. pylori </italic>[<xref rid="B50" ref-type="bibr">50</xref>, <xref rid="B51" ref-type="bibr">51</xref>], and only few studies evaluated the effect of herbal preparations as a stand alone or along with antacids. Zhang et al. reported that 14.43% of the subjects evaluated in a double-blind randomized placebo-controlled trial showed negative results for <italic>H. pylori</italic> after 90 days of supplementation with Cranberry juice [<xref rid="B32" ref-type="bibr">32</xref>]. Administration of 5&#x02009;g of vitamin C for 4 weeks in <italic>H. pylori</italic> positive patients with chronic gastritis resulted in recovery of 30% of the patients treated with vitamin C [<xref rid="B52" ref-type="bibr">52</xref>]. Treatment effects with 1&#x02009;g, 2&#x02009;g, and 3&#x02009;g <italic>Nigella sativa</italic> administered with omeprazole were 47.6%, 66.7%, and 47.8% [<xref rid="B53" ref-type="bibr">53</xref>], respectively, while as a stand alone supplement GutGard showed 56% cure rate. Results of earlier clinical studies provide insights on the eradication rates of mono-, dual, and triple therapies. The eradication rates reported for monotherapy was 0&#x02013;54%, and dual therapies revealed recovery rate of 50&#x02013;85%. Further the triple therapies that are recommended as first line option were reported to have a cure rate of 95% [<xref rid="B54" ref-type="bibr">54</xref>, <xref rid="B55" ref-type="bibr">55</xref>]. However, in actual clinical settings even the triple therapies have been reported to have shown eradication rates of less than 80% [<xref rid="B56" ref-type="bibr">56</xref>, <xref rid="B57" ref-type="bibr">57</xref>]. The results of acid stable effective monotherapy for the treatment of <italic>H. pylori </italic> as a stand alone were comparable to GutGard cure rates. The fact that the eradication rates in clinical settings for antibiotic regimens are very low indicates preexisting resistance of <italic>H. pylori</italic> to antibiotics due to wide spread use of antibiotics for other indications, side effects, and premature discontinuation of antibiotic use. In such a scenario, GutGard that is well tolerated, safe, and with effective cure rates would be a better alternative for the management of <italic>H. pylori</italic>. As there are genetic differences in <italic>H. pylori</italic> strains in east and west [<xref rid="B58" ref-type="bibr">58</xref>], further research in different locations and investigating the effect of GutGard in subjects resistant to antibiotics, subjects with treatment failure to triple therapy, or evaluating effectiveness of GutGard in combination with proton pump inhibitors/other antibiotics as dual or triple therapy will further establish the effectiveness of GutGard.</p><p>The activity of GutGard on gastric <italic>H. pylori</italic> may be explained by various possible mechanisms. Based on the findings by Fukai et al. [<xref rid="B38" ref-type="bibr">38</xref>], about the anti-<italic>H. pylori</italic> activity of licorice, the anti-microbial activity of GutGard was investigated using <italic>in vitro</italic> assays such as DNA gyrase inhibition, protein synthesis inhibition, and dihydrofolate reductase (DHFR) enzyme inhibition. DNA gyrase is an essential bacterial enzyme that catalyzes the ATP-dependent negative supercoiling of double-stranded closed-circular DNA. DNA gyrase is vital for transcription and replication of bacteria [<xref rid="B59" ref-type="bibr">59</xref>]; inhibition of DNA gyrase appears to be an opt target for anti-microbials. GutGard has shown activity by inhibiting DNA gyrase [<xref rid="B60" ref-type="bibr">60</xref>]; the results are in accordance with the study published by Hui et al. [<xref rid="B61" ref-type="bibr">61</xref>]. Interestingly, GutGard also inhibited protein synthesis and DHFR enzyme <italic>in vitro</italic> [<xref rid="B60" ref-type="bibr">60</xref>]. Blockade of DHFR causes cell death through inhibition of DNA synthesis and is considered suitable target for inhibition of <italic>H. pylori</italic> replication [<xref rid="B62" ref-type="bibr">62</xref>]. The aforementioned mechanisms may attribute to the effect of GutGard on <italic>H. pylori </italic> management. </p><p>GutGard was found to be safe and well tolerated. Few side effects, namely, nausea, diarrhoea, headache, throat pain, vomiting, cold and cough, body pain, acidity, body heat, fever, and pain in stomach were observed mostly in both placebo and GutGard treated groups. However, side-effects recorded did not reveal any significant differences between treatment groups and were found to be non-treatment-related. The published literature on clinical studies of licorice formulations also did not report any significant adverse events that indicate the safe nature of the dietary supplement [<xref rid="B24" ref-type="bibr">24</xref>]. The safety on present intake levels of GutGard is also affirmed in the study by Raveendra et al. [<xref rid="B29" ref-type="bibr">29</xref>]. </p></sec><sec id="sec5"><title>5. Conclusion</title><p>In conclusion, the findings of the randomized double blind placebo controlled trial on GutGard, extract of <italic>G. glabra</italic> revealed significant decrease in the <italic>H. pylori</italic>, gastric load as compared to placebo and was found to be safe and well tolerated. In the present study, treatment with GutGard was found to be 73.2% or 3.73 times more effective than placebo. Hence GutGard supplementation can be considered an effective alternative remedy for the management of <italic>H. pylori</italic>.</p></sec></body><back><ack><title>Acknowledgment</title><p>The authors thankfully acknowledge the financial assistance provided by NICS Co., Ltd., Seoul, Republic of Korea for the project. </p></ack><ref-list><ref id="B1"><label>1</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Marshall</surname><given-names>JB</given-names></name></person-group><source><italic>One Hundred Years of Discovery and Rediscovery of Helicobacter pylori and Its Association With Peptic Ulcer Disease Chapter 3</italic></source><year>2001</year><publisher-loc>Washington, DC, USA</publisher-loc><publisher-name>ASM Press</publisher-name></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunt</surname><given-names>RH</given-names></name><name><surname>Xiao</surname><given-names>SD</given-names></name><name><surname>Megraud</surname><given-names>F</given-names></name><etal/></person-group><article-title>
<italic>Helicobacter pylori</italic> in developing countries</article-title><source><italic>Journal of Gastrointestinal and Liver Diseases</italic></source><year>2011</year><volume>20</volume><issue>3</issue><fpage>299</fpage><lpage>304</lpage><pub-id pub-id-type="pmid">21961099</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nomura</surname><given-names>A</given-names></name><name><surname>Stemmermann</surname><given-names>GN</given-names></name><name><surname>Chyou</surname><given-names>PH</given-names></name><name><surname>Perez-Perez</surname><given-names>GI</given-names></name><name><surname>Blaser</surname><given-names>MJ</given-names></name></person-group><article-title>
<italic>Helicobacter pylori</italic> infection and the risk for duodenal and gastric ulceration</article-title><source><italic>Annals of Internal Medicine</italic></source><year>1994</year><volume>120</volume><issue>12</issue><fpage>977</fpage><lpage>981</lpage><pub-id pub-id-type="other">2-s2.0-0028292275</pub-id><pub-id pub-id-type="pmid">7741826</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adamu</surname><given-names>MA</given-names></name><name><surname>Schottker</surname><given-names>B</given-names></name><name><surname>Weck</surname><given-names>MN</given-names></name><name><surname>Brenner</surname><given-names>H</given-names></name></person-group><article-title>
<italic>Helicobacter pylori</italic> infection is strongly associated with gastric and duodenal ulcers in a large prospective study</article-title><source><italic>Clinical Gastroenterology and Hepatology</italic></source><year>2012</year><volume>10</volume><issue>5</issue><fpage>487</fpage><lpage>493</lpage><pub-id pub-id-type="pmid">22230167</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>WQ</given-names></name><name><surname>Zhou</surname><given-names>YQ</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><etal/></person-group><article-title>The Eradicating <italic>Helicobacter pylori</italic> infection in duodenal ulcer patients by three short-term triple therapies in China: a multicenter clinical comparative study</article-title><source><italic>Hepato-Gastroenterology</italic></source><year>2012</year><volume>59</volume><issue>133</issue><fpage>296</fpage><lpage>299</lpage><pub-id pub-id-type="pmid">22260837</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uemura</surname><given-names>N</given-names></name><name><surname>Okamoto</surname><given-names>S</given-names></name><name><surname>Yamamoto</surname><given-names>S</given-names></name><etal/></person-group><article-title>
<italic>Helicobacter pylori</italic> infection and the development of gastric cancer</article-title><source><italic>The New England Journal of Medicine</italic></source><year>2001</year><volume>345</volume><issue>11</issue><fpage>784</fpage><lpage>789</lpage><pub-id pub-id-type="pmid">11556297</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuccio</surname><given-names>L</given-names></name><name><surname>Zagari</surname><given-names>RM</given-names></name><name><surname>Eusebi</surname><given-names>LH</given-names></name><etal/></person-group><article-title>Meta-analysis: can <italic>Helicobacter pylori</italic> eradication treatment reduce the risk for gastric cancer?</article-title><source><italic>Annals of Internal Medicine</italic></source><year>2009</year><volume>151</volume><issue>2</issue><fpage>121</fpage><lpage>128</lpage><pub-id pub-id-type="other">2-s2.0-67651091935</pub-id><pub-id pub-id-type="pmid">19620164</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montalban</surname><given-names>C</given-names></name><name><surname>Castrillo</surname><given-names>JM</given-names></name><name><surname>Abraira</surname><given-names>V</given-names></name><etal/></person-group><article-title>Gastric B-cell mucosa-associated lymphoid tissue (MALT) lymphoma. Clinicopathological study and evaluation of the prognostic factors in 143 patients</article-title><source><italic>Annals of Oncology</italic></source><year>1995</year><volume>6</volume><issue>4</issue><fpage>355</fpage><lpage>362</lpage><pub-id pub-id-type="other">2-s2.0-0028931021</pub-id><pub-id pub-id-type="pmid">7619750</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owens</surname><given-names>SR</given-names></name><name><surname>Smith</surname><given-names>LB</given-names></name></person-group><article-title>Molecular aspects of <italic>H. pylori</italic>-related MALT lymphoma</article-title><source><italic>Pathology Research International</italic></source><year>2011</year><volume>2011</volume><fpage>8 pages</fpage><pub-id pub-id-type="publisher-id">193149</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malfertheiner</surname><given-names>P</given-names></name><name><surname>Megraud</surname><given-names>F</given-names></name><name><surname>O'Morain</surname><given-names>C</given-names></name><etal/></person-group><article-title>Current concepts in the management of <italic>Helicobacter pylori</italic> infection: the maastricht III consensus report</article-title><source><italic>Gut</italic></source><year>2007</year><volume>56</volume><issue>6</issue><fpage>772</fpage><lpage>781</lpage><pub-id pub-id-type="pmid">17170018</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chey</surname><given-names>WD</given-names></name><name><surname>Wong</surname><given-names>BC</given-names></name></person-group><article-title>American College of Gastroenterology guideline on the management of <italic>Helicobacter pylori</italic> infection</article-title><source><italic>The American Journal of Gastroenterology</italic></source><year>2007</year><volume>102</volume><issue>8</issue><fpage>1808</fpage><lpage>1825</lpage><pub-id pub-id-type="pmid">17608775</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischbach</surname><given-names>L</given-names></name><name><surname>Evans</surname><given-names>EL</given-names></name></person-group><article-title>Meta-analysis: The effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for <italic>Helicobacter pylori</italic>
</article-title><source><italic>Alimentary Pharmacology and Therapeutics</italic></source><year>2007</year><volume>26</volume><issue>3</issue><fpage>343</fpage><lpage>357</lpage><pub-id pub-id-type="other">2-s2.0-34447298402</pub-id><pub-id pub-id-type="pmid">17635369</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Francesco</surname><given-names>V</given-names></name><name><surname>Giorgio</surname><given-names>F</given-names></name><name><surname>Hassan</surname><given-names>C</given-names></name><etal/></person-group><article-title>Worldwide <italic>H. pylori</italic> antibiotic resistance: a systematic review</article-title><source><italic>Journal of Gastrointestinal and Liver Diseases</italic></source><year>2010</year><volume>19</volume><issue>4</issue><fpage>409</fpage><lpage>414</lpage><pub-id pub-id-type="pmid">21188333</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basset</surname><given-names>C</given-names></name><name><surname>Holton</surname><given-names>J</given-names></name><name><surname>Gatta</surname><given-names>L</given-names></name><etal/></person-group><article-title>
<italic>Helicobacter pylori</italic> infection: anything new should we know?</article-title><source><italic>Alimentary Pharmacology and Therapeutics</italic></source><year>2004</year><volume>20</volume><issue>2</issue><fpage>31</fpage><lpage>41</lpage><pub-id pub-id-type="other">2-s2.0-4544333193</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000e9;graud</surname><given-names>F</given-names></name></person-group><article-title>
<italic>H. pylori</italic> antibiotic resistance: prevalence, importance, and advances in testing</article-title><source><italic>Gut</italic></source><year>2004</year><volume>53</volume><issue>9</issue><fpage>1374</fpage><lpage>1384</lpage><pub-id pub-id-type="pmid">15306603</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Mahony</surname><given-names>R</given-names></name><name><surname>Al-Khtheeri</surname><given-names>H</given-names></name><name><surname>Weerasekera</surname><given-names>D</given-names></name><etal/></person-group><article-title>Bactericidal and anti-adhesive properties of culinary and medicinal plants against <italic>Helicobacter pylori</italic>
</article-title><source><italic>World Journal of Gastroenterology</italic></source><year>2005</year><volume>11</volume><issue>47</issue><fpage>7499</fpage><lpage>7507</lpage><pub-id pub-id-type="other">2-s2.0-31144473388</pub-id><pub-id pub-id-type="pmid">16437723</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hikino</surname><given-names>H</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Wagner</surname><given-names>H</given-names></name><name><surname>Hikino</surname><given-names>H</given-names></name><name><surname>Farnsworth</surname><given-names>NR</given-names></name></person-group><article-title>Recent research on oriental medicinal plants</article-title><source><italic>Economic and Medicinal Plant Research</italic></source><year>1985</year><publisher-loc>London, UK</publisher-loc><publisher-name>Academic Press</publisher-name><fpage>53</fpage><lpage>85</lpage></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaya</surname><given-names>J</given-names></name><name><surname>Belinky</surname><given-names>PA</given-names></name><name><surname>Aviram</surname><given-names>M</given-names></name></person-group><article-title>Antioxidant constituents from licorice roots: isolation, structure elucidation and antioxidative capacity toward LDL oxidation</article-title><source><italic>Free Radical Biology and Medicine</italic></source><year>1997</year><volume>23</volume><issue>2</issue><fpage>302</fpage><lpage>313</lpage><pub-id pub-id-type="other">2-s2.0-0030959281</pub-id><pub-id pub-id-type="pmid">9199893</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lata</surname><given-names>S</given-names></name><name><surname>Kakkar</surname><given-names>S</given-names></name><name><surname>Srivastava</surname><given-names>VK</given-names></name><name><surname>Saxena</surname><given-names>KK</given-names></name><name><surname>Saxena</surname><given-names>RS</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name></person-group><article-title>Comparative antipyretic activity of <italic>Ocimum sanctum, Glycyrrhiza glabra</italic> and aspirin in experimentally-induced pyrexia in rats</article-title><source><italic>Indian Journal of Pharmacology</italic></source><year>1999</year><volume>31</volume><issue>1</issue><fpage>71</fpage><lpage>75</lpage></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wittschier</surname><given-names>N</given-names></name><name><surname>Faller</surname><given-names>G</given-names></name><name><surname>Hensel</surname><given-names>A</given-names></name></person-group><article-title>Aqueous extracts and polysaccharides from Liquorice roots (<italic>Glycyrrhiza glabra</italic> L.) inhibit adhesion of <italic>Helicobacter pylori</italic> to human gastric mucosa</article-title><source><italic>Journal of Ethnopharmacology</italic></source><year>2009</year><volume>125</volume><issue>2</issue><fpage>218</fpage><lpage>223</lpage><pub-id pub-id-type="other">2-s2.0-68849125227</pub-id><pub-id pub-id-type="pmid">19607905</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>S</given-names></name><name><surname>Inoue</surname><given-names>A</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Tanji</surname><given-names>M</given-names></name><name><surname>Kiyama</surname><given-names>R</given-names></name></person-group><article-title>Activation of rapid signaling pathways and the subsequent transcriptional regulation for the proliferation of breast cancer MCF-7 cells by the treatment with an extract of <italic>Glycyrrhiza glabra</italic> root</article-title><source><italic>Food and Chemical Toxicology</italic></source><year>2007</year><volume>45</volume><issue>12</issue><fpage>2470</fpage><lpage>2478</lpage><pub-id pub-id-type="other">2-s2.0-35348998912</pub-id><pub-id pub-id-type="pmid">17664038</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zore</surname><given-names>GB</given-names></name><name><surname>Winston</surname><given-names>UB</given-names></name><name><surname>Surwase</surname><given-names>BS</given-names></name><etal/></person-group><article-title>Chemoprofile and bioactivities of <italic>Taverniera cuneifolia</italic> (Roth) Arn.: a wild relative and possible substitute of <italic>Glycyrrhiza glabra</italic> L.</article-title><source><italic>Phytomedicine</italic></source><year>2008</year><volume>15</volume><issue>4</issue><fpage>292</fpage><lpage>300</lpage><pub-id pub-id-type="other">2-s2.0-41049109855</pub-id><pub-id pub-id-type="pmid">17350239</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>VK</given-names></name><name><surname>Fatima</surname><given-names>A</given-names></name><name><surname>Faridi</surname><given-names>U</given-names></name><etal/></person-group><article-title>Antimicrobial potential of<italic>Glycyrrhiza glabra</italic>roots</article-title><source><italic>Journal of Ethnopharmacology</italic></source><year>2008</year><volume>116</volume><issue>2</issue><fpage>377</fpage><lpage>380</lpage><pub-id pub-id-type="pmid">18182260</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larkworthy</surname><given-names>W</given-names></name><name><surname>Holgate</surname><given-names>PF</given-names></name></person-group><article-title>Deglycyrrhizinized liquorice in the treatment of chronic duodenal ulcer. A retrospective endoscopic survey of 32 patients</article-title><source><italic>Practitioner</italic></source><year>1975</year><volume>215</volume><issue>1290</issue><fpage>787</fpage><lpage>792</lpage><pub-id pub-id-type="other">2-s2.0-0016747190</pub-id><pub-id pub-id-type="pmid">772652</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bennett</surname><given-names>A</given-names></name><name><surname>Clark-Wibberley</surname><given-names>T</given-names></name><name><surname>Stamford</surname><given-names>IF</given-names></name><name><surname>Wright</surname><given-names>JE</given-names></name></person-group><article-title>Aspirin-induced gastric mucosal damage in rats: cimetidine and deglycyrrhizinated liquorice together give greater protection than low doses of either drug alone</article-title><source><italic>Journal of Pharmacy and Pharmacology</italic></source><year>1980</year><volume>32</volume><issue>2</issue><fpage>p. 151</fpage><pub-id pub-id-type="other">2-s2.0-0018889826</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Feldman</surname><given-names>RA</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Achtman</surname><given-names>M</given-names></name><name><surname>Suerbaum</surname><given-names>S</given-names></name></person-group><article-title>Epidemiologic observations and open questions about disease and infection caused by <italic>Helicobacter pylori</italic>
</article-title><source><italic>
Helicobacter pylori: Molecular and Cellular Biology</italic></source><year>2001</year><publisher-loc>Wymondham, UK</publisher-loc><publisher-name>Horizon Scientific Press</publisher-name><fpage>29</fpage><lpage>51</lpage></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>LI</given-names></name><name><surname>Yan-li</surname><given-names>GE</given-names></name><name><surname>Yong-hui</surname><given-names>Lin</given-names></name><name><surname>Zhi-rong</surname><given-names>Wang</given-names></name><name><surname>Qiong</surname><given-names>Wu</given-names></name><name><surname>Jun-jie</surname><given-names>Zhang</given-names></name></person-group><article-title>Experimental study of the effect of <italic>Glycyrrhiza</italic> flavonoids on gastric cancer in vivo</article-title><source><italic>Journal of Tongji University</italic></source><year>2010</year></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandrasekaran</surname><given-names>CV</given-names></name><name><surname>Sundarajan</surname><given-names>K</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Srikanth</surname><given-names>HS</given-names></name><name><surname>Edwin</surname><given-names>J</given-names></name><name><surname>Agarwal</surname><given-names>A</given-names></name></person-group><article-title>Evaluation of the genotoxic potential of standardized extract of <italic>Glycyrrhiza glabra</italic> (GutGard)</article-title><source><italic>Regulatory Toxicology and Pharmacology</italic></source><year>2011</year><volume>61</volume><issue>3</issue><fpage>373</fpage><lpage>380</lpage><pub-id pub-id-type="pmid">22019788</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raveendra</surname><given-names>KR</given-names></name><name><surname>Jayachandra</surname></name><name><surname>Srinivasa</surname><given-names>V</given-names></name></person-group><article-title>An extract of <italic>Glycyrrhiza glabra</italic> (GutGard) alleviates symptoms of functional dyspepsia: a randomized, double-blind, placebo-controlled study</article-title><source><italic>Evidence-Based Complementary and Alternative Medicine</italic></source><year>2012</year><volume>2012</volume><pub-id pub-id-type="publisher-id">216970</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukherjee</surname><given-names>M</given-names></name><name><surname>Bhaskaran</surname><given-names>N</given-names></name><name><surname>Srinath</surname><given-names>R</given-names></name><etal/></person-group><article-title>Anti-ulcer and antioxidant activity of GutGard</article-title><source><italic>Indian Journal of Experimental Biology</italic></source><year>2010</year><volume>48</volume><issue>3</issue><fpage>269</fpage><lpage>274</lpage><pub-id pub-id-type="other">2-s2.0-77954251704</pub-id><pub-id pub-id-type="pmid">21046980</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>van Belle</surname><given-names>G</given-names></name><name><surname>Millard</surname><given-names>StevenP</given-names></name></person-group><source><italic>STRUTS Statistical Rules of Thumb</italic></source><publisher-loc>Seattle, Wash, USA</publisher-loc><publisher-name>University of Washington</publisher-name></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Pan</surname><given-names>K</given-names></name><name><surname>Go</surname><given-names>VL</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>You</surname><given-names>WC</given-names></name></person-group><article-title>Efficacy of cranberry juice on <italic>Helicobacter pylori</italic> infection: a double-blind, randomized placebo-controlled trial</article-title><source><italic>Helicobacter</italic></source><year>2005</year><volume>10</volume><issue>2</issue><fpage>139</fpage><lpage>145</lpage><pub-id pub-id-type="other">2-s2.0-16444369986</pub-id><pub-id pub-id-type="pmid">15810945</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asaka</surname><given-names>M</given-names></name><name><surname>Kato</surname><given-names>M</given-names></name><name><surname>Takahashi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Guidelines for the management of <italic>Helicobacter pylori</italic> infection in Japan: 2009 revised edition</article-title><source><italic>Helicobacter</italic></source><year>2010</year><volume>15</volume><issue>1</issue><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="other">2-s2.0-74349106695</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iimuro</surname><given-names>M</given-names></name><name><surname>Shibata</surname><given-names>H</given-names></name><name><surname>Kawamori</surname><given-names>T</given-names></name><etal/></person-group><article-title>Suppressive effects of garlic extract on <italic>Helicobacter pylori</italic>-induced gastritis in Mongolian gerbils</article-title><source><italic>Cancer Letters</italic></source><year>2002</year><volume>187</volume><issue>1-2</issue><fpage>61</fpage><lpage>68</lpage><pub-id pub-id-type="other">2-s2.0-0037058660</pub-id><pub-id pub-id-type="pmid">12359352</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsubara</surname><given-names>S</given-names></name><name><surname>Shibata</surname><given-names>H</given-names></name><name><surname>Ishikawa</surname><given-names>F</given-names></name><etal/></person-group><article-title>Suppression of <italic>Helicobacter pylori</italic>-induced gastritis by green tea extract in Mongolian gerbils</article-title><source><italic>Biochemical and Biophysical Research Communications</italic></source><year>2003</year><volume>310</volume><issue>3</issue><fpage>715</fpage><lpage>719</lpage><pub-id pub-id-type="other">2-s2.0-0141757322</pub-id><pub-id pub-id-type="pmid">14550260</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nariman</surname><given-names>F</given-names></name><name><surname>Eftekhar</surname><given-names>F</given-names></name><name><surname>Habibi</surname><given-names>Z</given-names></name><name><surname>Falsafi</surname><given-names>T</given-names></name></person-group><article-title>Anti-<italic>Helicobacter pylori</italic> activities of six Iranian plants</article-title><source><italic>Helicobacter</italic></source><year>2004</year><volume>9</volume><issue>2</issue><fpage>146</fpage><lpage>151</lpage><pub-id pub-id-type="other">2-s2.0-1942504701</pub-id><pub-id pub-id-type="pmid">15068416</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lengsfeld</surname><given-names>C</given-names></name><name><surname>Titgemeyer</surname><given-names>F</given-names></name><name><surname>Faller</surname><given-names>G</given-names></name><name><surname>Hensel</surname><given-names>A</given-names></name></person-group><article-title>Glycosylated compounds from Okra inhibit adhesion of <italic>Helicobacter pylori</italic> to human gastric mucosa</article-title><source><italic>Journal of Agricultural and Food Chemistry</italic></source><year>2004</year><volume>52</volume><issue>6</issue><fpage>1495</fpage><lpage>1503</lpage><pub-id pub-id-type="other">2-s2.0-1642344593</pub-id><pub-id pub-id-type="pmid">15030201</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukai</surname><given-names>T</given-names></name><name><surname>Marumo</surname><given-names>A</given-names></name><name><surname>Kaitou</surname><given-names>K</given-names></name><name><surname>Kanda</surname><given-names>T</given-names></name><name><surname>Terada</surname><given-names>S</given-names></name><name><surname>Nomura</surname><given-names>T</given-names></name></person-group><article-title>Anti-<italic>Helicobacter pylori</italic> flavonoids from licorice extract</article-title><source><italic>Life Sciences</italic></source><year>2002</year><volume>71</volume><issue>12</issue><fpage>1449</fpage><lpage>1463</lpage><pub-id pub-id-type="other">2-s2.0-0037047461</pub-id><pub-id pub-id-type="pmid">12127165</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krausse</surname><given-names>R</given-names></name><name><surname>Bielenberg</surname><given-names>J</given-names></name><name><surname>Blaschek</surname><given-names>W</given-names></name><name><surname>Ullmann</surname><given-names>U</given-names></name></person-group><article-title>In vitro anti-<italic>Helicobacter pylori</italic> activity of <italic>Extractum liquiritiae</italic>, glycyrrhizin and its metabolites</article-title><source><italic>Journal of Antimicrobial Chemotherapy</italic></source><year>2004</year><volume>54</volume><issue>1</issue><fpage>243</fpage><lpage>246</lpage><pub-id pub-id-type="other">2-s2.0-3543082288</pub-id><pub-id pub-id-type="pmid">15190039</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>D</given-names></name><name><surname>Eishi</surname><given-names>Y</given-names></name><name><surname>Ohkusa</surname><given-names>T</given-names></name><etal/></person-group><article-title>Gastric mucosal density of <italic>Helicobacter pylori</italic> estimated by real-time PCR compared with results of urea breath test and histological grading</article-title><source><italic>Journal of Medical Microbiology</italic></source><year>2002</year><volume>51</volume><issue>4</issue><fpage>305</fpage><lpage>311</lpage><pub-id pub-id-type="other">2-s2.0-0036196015</pub-id><pub-id pub-id-type="pmid">11926735</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Francesco</surname><given-names>V</given-names></name><name><surname>Zullo</surname><given-names>A</given-names></name><name><surname>Perna</surname><given-names>F</given-names></name><etal/></person-group><article-title>
<italic>Helicobacter pylori</italic> antibiotic resistance and [13C] urea breath test values</article-title><source><italic>Journal of Medical Microbiology</italic></source><year>2010</year><volume>59</volume><issue>5</issue><fpage>588</fpage><lpage>591</lpage><pub-id pub-id-type="other">2-s2.0-77951651471</pub-id><pub-id pub-id-type="pmid">20093375</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perri</surname><given-names>F</given-names></name><name><surname>Clemente</surname><given-names>R</given-names></name><name><surname>Pastore</surname><given-names>M</given-names></name><etal/></person-group><article-title>The 13C-urea breath test as a predictor of intragastric bacterial load and severity of <italic>Helicobacter pylori</italic> gastritis</article-title><source><italic>Scandinavian Journal of Clinical and Laboratory Investigation</italic></source><year>1998</year><volume>58</volume><issue>1</issue><fpage>19</fpage><lpage>27</lpage><pub-id pub-id-type="other">2-s2.0-6844254560</pub-id><pub-id pub-id-type="pmid">9516653</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zagari</surname><given-names>RM</given-names></name><name><surname>Pozzato</surname><given-names>P</given-names></name><name><surname>Martuzzi</surname><given-names>C</given-names></name><etal/></person-group><article-title>
<sup>13</sup>C-urea breath test to assess <italic>Helicobacter pylori</italic> bacterial load</article-title><source><italic>Helicobacter</italic></source><year>2005</year><volume>10</volume><issue>6</issue><fpage>615</fpage><lpage>619</lpage><pub-id pub-id-type="other">2-s2.0-27944446079</pub-id><pub-id pub-id-type="pmid">16302988</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cremonini</surname><given-names>F</given-names></name><name><surname>Bartolozzi</surname><given-names>F</given-names></name><name><surname>Armuzzi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Can <sup>13</sup>C urea breath test predict resistance to therapy in <italic>Helicobacter pylori</italic> infection?</article-title><source><italic>Hepato-Gastroenterology</italic></source><year>2005</year><volume>52</volume><issue>64</issue><fpage>1119</fpage><lpage>1121</lpage><pub-id pub-id-type="other">2-s2.0-21744453452</pub-id><pub-id pub-id-type="pmid">16001643</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zullo</surname><given-names>A</given-names></name><name><surname>Sanchez-Mete</surname><given-names>L</given-names></name><name><surname>Hassan</surname><given-names>C</given-names></name><etal/></person-group><article-title>
<italic>Helicobacter pylori</italic> density and cagA status in cirrhotic patients: a case-control study</article-title><source><italic>Journal of Gastroenterology and Hepatology</italic></source><year>2004</year><volume>19</volume><issue>10</issue><fpage>1174</fpage><lpage>1178</lpage><pub-id pub-id-type="other">2-s2.0-5644239894</pub-id><pub-id pub-id-type="pmid">15377296</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarker</surname><given-names>SA</given-names></name><name><surname>Nahar</surname><given-names>S</given-names></name><name><surname>Rahman</surname><given-names>M</given-names></name><etal/></person-group><article-title>High prevalence of cagA and vacA seropositivity in asymptomatic Bangladeshi children with <italic>Helicobacter pylori</italic> infection</article-title><source><italic>Acta Paediatrica</italic></source><year>2004</year><volume>93</volume><issue>11</issue><fpage>1432</fpage><lpage>1436</lpage><pub-id pub-id-type="other">2-s2.0-7644244312</pub-id><pub-id pub-id-type="pmid">15513567</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaira</surname><given-names>D</given-names></name><name><surname>Malfertheiner</surname><given-names>P</given-names></name><name><surname>M&#x000e9;graud</surname><given-names>F</given-names></name><etal/></person-group><article-title>Diagnosis of <italic>Helicobacter pylori</italic> infection with a new non-invasive antigen-based assay</article-title><source><italic>The Lancet</italic></source><year>1999</year><volume>354</volume><issue>9172</issue><fpage>30</fpage><lpage>33</lpage><pub-id pub-id-type="other">2-s2.0-0033519985</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaira</surname><given-names>D</given-names></name><name><surname>Malfertheiner</surname><given-names>P</given-names></name><name><surname>Megraud</surname><given-names>F</given-names></name><etal/></person-group><article-title>Noninvasive antigen-based assay for assessing <italic>Helicobacter pylori</italic> eradication: a European multicenter study</article-title><source><italic>The American Journal of Gastroenterology</italic></source><year>2000</year><volume>95</volume><issue>4</issue><fpage>925</fpage><lpage>929</lpage><pub-id pub-id-type="pmid">10763939</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaira</surname><given-names>D</given-names></name><name><surname>Vakil</surname><given-names>N</given-names></name><name><surname>Menegatti</surname><given-names>M</given-names></name><etal/></person-group><article-title>The stool antigen test for detection of <italic>Helicobacter pylori</italic> after eradication therapy</article-title><source><italic>Annals of Internal Medicine</italic></source><year>2002</year><volume>136</volume><issue>4</issue><fpage>280</fpage><lpage>287</lpage><pub-id pub-id-type="other">2-s2.0-0037133094</pub-id><pub-id pub-id-type="pmid">11848725</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Myllyluoma</surname><given-names>E</given-names></name><name><surname>Veijola</surname><given-names>L</given-names></name><name><surname>Ahlroos</surname><given-names>T</given-names></name><etal/></person-group><article-title>Probiotic supplementation improves tolerance to <italic>Helicobacter pylori</italic> eradication therapy: a placebo-controlled, double-blind randomized pilot study</article-title><source><italic>Alimentary Pharmacology and Therapeutics</italic></source><year>2005</year><volume>21</volume><issue>10</issue><fpage>1263</fpage><lpage>1272</lpage><pub-id pub-id-type="other">2-s2.0-19544363425</pub-id><pub-id pub-id-type="pmid">15882248</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SJ</given-names></name><name><surname>Park</surname><given-names>JY</given-names></name><name><surname>Choi</surname><given-names>KS</given-names></name><etal/></person-group><article-title>Efficacy of Korean red ginseng supplementation on eradication rate and gastric volatile sulfur compound levels after <italic>Helicobacter pylori</italic> eradication therapy</article-title><source><italic>Journal of Ginseng Research</italic></source><year>2010</year><volume>34</volume><issue>2</issue><fpage>122</fpage><lpage>131</lpage><pub-id pub-id-type="other">2-s2.0-79951780193</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jarosz</surname><given-names>M</given-names></name><name><surname>Dzieniszewski</surname><given-names>J</given-names></name><name><surname>Dabrowska-Ufniarz</surname><given-names>E</given-names></name><name><surname>Wartanowicz</surname><given-names>M</given-names></name><name><surname>Ziemlanski</surname><given-names>S</given-names></name><name><surname>Reed</surname><given-names>P</given-names></name></person-group><article-title>Effects of high dose vitamin C treatment on <italic>Helicobacter pylori</italic> infection and total vitamin C concentration in gastric juice</article-title><source><italic>European Journal of Cancer Prevention</italic></source><year>1998</year><volume>7</volume><issue>6</issue><fpage>449</fpage><lpage>454</lpage><pub-id pub-id-type="other">2-s2.0-0032424704</pub-id><pub-id pub-id-type="pmid">9926292</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salem</surname><given-names>EM</given-names></name><name><surname>Yar</surname><given-names>T</given-names></name><name><surname>Bamosa</surname><given-names>AO</given-names></name><etal/></person-group><article-title>Comparative study of <italic>Nigella Sativa</italic> and triple therapy in eradication of <italic>Helicobacter pylori</italic> in patients with non-ulcer dyspepsia</article-title><source><italic>Saudi Journal of Gastroenterology</italic></source><year>2010</year><volume>16</volume><issue>3</issue><fpage>207</fpage><lpage>214</lpage><pub-id pub-id-type="other">2-s2.0-77954782431</pub-id><pub-id pub-id-type="pmid">20616418</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peterson</surname><given-names>WL</given-names></name><name><surname>Graham</surname><given-names>DY</given-names></name><name><surname>Marshall</surname><given-names>B</given-names></name><etal/></person-group><article-title>Clarithromycin as monotherapy for eradication of <italic>Helicobacter pylori</italic>: a randomized, double-blind trial</article-title><source><italic>The American Journal of Gastroenterology</italic></source><year>1993</year><volume>88</volume><issue>11</issue><fpage>1860</fpage><lpage>1864</lpage><pub-id pub-id-type="pmid">8237933</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joshi</surname><given-names>YK</given-names></name></person-group><article-title>
<italic>Helicobacter pylori</italic> infection: current status</article-title><source><italic>Journal of Indian Academy of Clinical Medicine</italic></source><year>2000</year><volume>5</volume><issue>2</issue><fpage>148</fpage><lpage>155</lpage></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thyagarajan</surname><given-names>SP</given-names></name><name><surname>Ray</surname><given-names>P</given-names></name><name><surname>Das</surname><given-names>BK</given-names></name><etal/></person-group><article-title>Geographical difference in antimicrobial resistance pattern of <italic>H. pylori</italic> clinical isolates from Indian patients: multicentric study</article-title><source><italic>Journal of Gastroenterology and Hepatology</italic></source><year>2003</year><volume>18</volume><issue>12</issue><fpage>1373</fpage><lpage>1378</lpage><pub-id pub-id-type="pmid">14675265</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talaie</surname><given-names>R</given-names></name><name><surname>Zojaji</surname><given-names>H</given-names></name><name><surname>Mirsattari</surname><given-names>D</given-names></name><name><surname>Kaboli</surname><given-names>A</given-names></name><name><surname>Alizadeh</surname><given-names>AHM</given-names></name><name><surname>Zali</surname><given-names>MR</given-names></name></person-group><article-title>Comparison of two different eradication regimens for <italic>H. pylori</italic>: amoxicillin, metronidazole, bismuth and omeprazole (OMAB) versus the new regimen of penbactam, clarithromycin and omeprazole (OPC), a randomized clinical trial</article-title><source><italic>Journal of Gastroenterology and Hepatology</italic></source><year>2008</year><volume>1</volume><issue>3</issue><fpage>19</fpage><lpage>22</lpage></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jang</surname><given-names>S</given-names></name><name><surname>Jones</surname><given-names>KR</given-names></name><name><surname>Olsen</surname><given-names>CH</given-names></name><etal/></person-group><article-title>Epidemiological link between gastric disease and polymorphisms in VacA and CagA</article-title><source><italic>Journal of Clinical Microbiology</italic></source><year>2010</year><volume>48</volume><issue>2</issue><fpage>559</fpage><lpage>567</lpage><pub-id pub-id-type="pmid">19955279</pub-id></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chatterji</surname><given-names>M</given-names></name><name><surname>Unniraman</surname><given-names>S</given-names></name><name><surname>Mahadevan</surname><given-names>S</given-names></name><name><surname>Nagaraja</surname><given-names>V</given-names></name></person-group><article-title>Effect of different classes of inhibitors on DNA gyrase from <italic>Mycobacterium smegmatis</italic>
</article-title><source><italic>Journal of Antimicrobial Chemotherapy</italic></source><year>2001</year><volume>48</volume><issue>4</issue><fpage>479</fpage><lpage>485</lpage><pub-id pub-id-type="other">2-s2.0-0034757527</pub-id><pub-id pub-id-type="pmid">11581225</pub-id></element-citation></ref><ref id="B60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asha</surname><given-names>MK</given-names></name><name><surname>Debraj</surname><given-names>D</given-names></name><name><surname>Prashanth</surname><given-names>D</given-names></name><etal/></person-group><article-title>In vitro anti-<italic>Helicobacter pylori</italic> activity of a flavonoid rich extract of <italic>Glycyrrhiza glabra</italic> and its probable mechanisms of action</article-title><source><italic> Journal of Ethnopharmacology</italic></source><year>2013</year><volume>145</volume><issue>2</issue><fpage>581</fpage><lpage>586</lpage><pub-id pub-id-type="pmid">23220194</pub-id></element-citation></ref><ref id="B61"><label>61</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Hui</surname><given-names>XU</given-names></name><name><surname>Pan</surname><given-names>YAO</given-names></name><name><surname>Guodong</surname><given-names>LIN</given-names></name><name><surname>Weiwen</surname><given-names>CHEN</given-names></name></person-group><article-title>In-vitro inhibitory effect of methanol extracts of Chinese herbal drugs on supercoiling activity of bacterial DNA Gyrase [OL]</article-title><comment>2011, <ext-link ext-link-type="uri" xlink:href="http://www.paper.edu.cn/index.php/default/en_releasepaper/content/4411791">http://www.paper.edu.cn/index.php/default/en_releasepaper/content/4411791</ext-link></comment></element-citation></ref><ref id="B62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendz</surname><given-names>GL</given-names></name><name><surname>Shepley</surname><given-names>AJ</given-names></name><name><surname>Hazell</surname><given-names>SL</given-names></name><name><surname>Smith</surname><given-names>MA</given-names></name></person-group><article-title>Purine metabolism and the microaerophily of <italic>Helicobacter pylori</italic>
</article-title><source><italic>Archives of Microbiology</italic></source><year>1997</year><volume>168</volume><issue>6</issue><fpage>448</fpage><lpage>456</lpage><pub-id pub-id-type="other">2-s2.0-0030732001</pub-id><pub-id pub-id-type="pmid">9385135</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Flow chart of disposition of subjects.</p></caption><graphic xlink:href="ECAM2013-263805.001"/></fig><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Characteristics of the subjects at baseline (mean &#x000b1; SD).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Parameters</th><th align="center" rowspan="1" colspan="1">GutGard (<italic>n</italic> = 50)</th><th align="center" rowspan="1" colspan="1">Placebo (<italic>n</italic> = 50)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Subjects (male/female)<break/>
</td><td align="center" rowspan="1" colspan="1">23/27</td><td align="center" rowspan="1" colspan="1">23/27</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (years)<break/>
</td><td align="center" rowspan="1" colspan="1">32.86 &#x000b1; 6.50<break/>
</td><td align="center" rowspan="1" colspan="1">33.10 &#x000b1; 5.59</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight (kg)<break/>
</td><td align="center" rowspan="1" colspan="1">62.60 &#x000b1; 7.43<break/>
</td><td align="center" rowspan="1" colspan="1">62.31 &#x000b1; 7.79<break/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Height (cms)</td><td align="center" rowspan="1" colspan="1">166.12 &#x000b1; 8.45</td><td align="center" rowspan="1" colspan="1">165.56 &#x000b1; 7.67</td></tr><tr><td align="left" rowspan="1" colspan="1">Heart rate/min<break/>
</td><td align="center" rowspan="1" colspan="1">69.34 &#x000b1; 4.30<break/>
</td><td align="center" rowspan="1" colspan="1">69.08 &#x000b1; 4.26<break/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">BP systolic (mmHg)<break/>
</td><td align="center" rowspan="1" colspan="1">116.72 &#x000b1; 6.44<break/>
</td><td align="center" rowspan="1" colspan="1">115.40 &#x000b1; 6.98<break/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">BP diastolic (mmHg)<break/>
</td><td align="center" rowspan="1" colspan="1">80.80 &#x000b1; 5.29<break/>
</td><td align="center" rowspan="1" colspan="1">80.28 &#x000b1; 4.43<break/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">HpSA <break/>
</td><td align="center" rowspan="1" colspan="1">Positive</td><td align="center" rowspan="1" colspan="1">Positive</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>&#x003b4;</italic> (means)<break/>
</td><td align="center" rowspan="1" colspan="1">7.12 &#x000b1; 1.36<break/>
</td><td align="center" rowspan="1" colspan="1">6.88 &#x000b1; 1.34<break/>
</td></tr></tbody></table><table-wrap-foot><fn><p>
<italic>P</italic> &#x02264; 0.05 versus placebo.</p></fn><fn><p>
<italic>&#x003b4;</italic>: delta over baseline value of <sup>13</sup>C urea breath test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Effect of GutGard on <italic>H. pylori</italic> gastric load (mean &#x000b1; SD).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Parameter</th><th align="center" rowspan="2" colspan="1">Groups</th><th align="center" rowspan="2" colspan="1">Day 0</th><th align="center" rowspan="2" colspan="1">Day 30</th><th align="center" rowspan="2" colspan="1">Day 60</th><th align="center" colspan="4" rowspan="1">Significance</th></tr><tr><th align="center" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">df</th><th align="center" rowspan="1" colspan="1">
<italic>F</italic> value</th><th align="center" rowspan="1" colspan="1">
<italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">DOB</td><td align="center" rowspan="1" colspan="1">GutGard</td><td align="center" rowspan="1" colspan="1">7.12 &#x000b1; 1.36</td><td align="center" rowspan="1" colspan="1">6.24 &#x000b1; 1.24</td><td align="center" rowspan="1" colspan="1">4.21 &#x000b1; 1.15</td><td align="center" rowspan="1" colspan="1">Group</td><td align="center" rowspan="1" colspan="1">1,98</td><td align="center" rowspan="1" colspan="1">5.63</td><td align="center" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1"> Placebo</td><td align="center" rowspan="1" colspan="1"> 6.88 &#x000b1; 1.34</td><td align="center" rowspan="1" colspan="1"> 6.40 &#x000b1; 1.31</td><td align="center" rowspan="1" colspan="1">6.10 &#x000b1; 1.30</td><td align="center" rowspan="1" colspan="1">Time</td><td align="center" rowspan="1" colspan="1">2,196</td><td align="center" rowspan="1" colspan="1">3047.10</td><td align="center" rowspan="1" colspan="1">0.00</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">Group &#x000d7; time</td><td align="center" rowspan="1" colspan="1">2,196</td><td align="center" rowspan="1" colspan="1">1120.27</td><td align="center" rowspan="1" colspan="1">0.00</td></tr></tbody></table></table-wrap><table-wrap id="tab3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Proportion of subjects turned from <italic>H. pylori</italic>&#x02014;positive (Hp<sup>+</sup>) to negative (Hp<sup>&#x02212;</sup>) status as measured by HpSA and <sup>13</sup>C-UBT.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Groups</th><th align="center" rowspan="2" colspan="1">Days</th><th align="center" rowspan="2" colspan="1">
<italic>n</italic>
</th><th align="center" colspan="2" rowspan="1">HpSA&#x02003;</th><th align="center" colspan="2" rowspan="1">
<sup>
13</sup>C-UBT&#x02003;</th></tr><tr><th align="center" rowspan="1" colspan="1">Hp<sup>+</sup>
</th><th align="center" rowspan="1" colspan="1">Hp<sup>&#x02212;</sup> (%)</th><th align="center" rowspan="1" colspan="1">Hp<sup>+</sup>
</th><th align="center" rowspan="1" colspan="1">Hp<sup>&#x02212;</sup> (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">GutGard </td><td align="center" rowspan="2" colspan="1">0</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Placebo</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" rowspan="1" colspan="1">GutGard </td><td align="center" rowspan="2" colspan="1">30</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Placebo</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" rowspan="1" colspan="1">GutGard </td><td align="center" rowspan="2" colspan="1">60</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">28* (56)</td><td align="center" rowspan="1" colspan="1">26</td><td align="center" rowspan="1" colspan="1">24* (48)</td></tr><tr><td align="left" rowspan="1" colspan="1">Placebo</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">48</td><td align="center" rowspan="1" colspan="1">2 (4)</td><td align="center" rowspan="1" colspan="1">49</td><td align="center" rowspan="1" colspan="1">1 (2)</td></tr></tbody></table><table-wrap-foot><fn><p>
<italic>n</italic>: no. of subjects; Hp<sup>&#x02212;</sup>: <italic>H. pylori</italic> negative; Hp<sup>+</sup>: <italic>H. pylori</italic> positive.</p></fn><fn><p>%: percentage of subjects turned from Hp Positive to Hp Negative.</p></fn><fn><p>*Significant difference compared to placebo.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Side effects during intervention period.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Side effect</th><th align="center" rowspan="1" colspan="1">GutGard <break/>(<italic>n</italic> = 50)<break/>
<italic>n</italic> (%)</th><th align="center" rowspan="1" colspan="1">Placebo<break/>(<italic>n</italic> = 50)<break/>
<italic>n</italic> (%)</th><th align="center" rowspan="1" colspan="1">
<italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Mild diarrhoea</td><td align="center" rowspan="1" colspan="1">5 (10)</td><td align="center" rowspan="1" colspan="1">2 (4)</td><td align="center" rowspan="1" colspan="1">0.24</td></tr><tr><td align="left" rowspan="1" colspan="1">Mild headache</td><td align="center" rowspan="1" colspan="1">1 (2)</td><td align="center" rowspan="1" colspan="1">1 (2)</td><td align="center" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Mild vomiting</td><td align="center" rowspan="1" colspan="1">3 (6)</td><td align="center" rowspan="1" colspan="1">1 (2)</td><td align="center" rowspan="1" colspan="1">0.30</td></tr><tr><td align="left" rowspan="1" colspan="1">Mild nausea</td><td align="center" rowspan="1" colspan="1">1 (2)</td><td align="center" rowspan="1" colspan="1">1 (2)</td><td align="center" rowspan="1" colspan="1">1.00 </td></tr><tr><td align="left" rowspan="1" colspan="1"> Mild throat pain</td><td align="center" rowspan="1" colspan="1">1 (2)</td><td align="center" rowspan="1" colspan="1">1 (2)</td><td align="center" rowspan="1" colspan="1">1.00 </td></tr><tr><td align="left" rowspan="1" colspan="1"> Mild cold and cough</td><td align="center" rowspan="1" colspan="1">1 (2)</td><td align="center" rowspan="1" colspan="1">1 (2)</td><td align="center" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Mild body pain</td><td align="center" rowspan="1" colspan="1">1 (2)</td><td align="center" rowspan="1" colspan="1">1 (2)</td><td align="center" rowspan="1" colspan="1">1.00 </td></tr><tr><td align="left" rowspan="1" colspan="1">Mild fever</td><td align="center" rowspan="1" colspan="1">2 (4)</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.15 </td></tr><tr><td align="left" rowspan="1" colspan="1">Moderate fever </td><td align="center" rowspan="1" colspan="1">1 (2)</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.31</td></tr><tr><td align="left" rowspan="1" colspan="1">Acidity</td><td align="center" rowspan="1" colspan="1">1 (2)</td><td align="center" rowspan="1" colspan="1">1 (2)</td><td align="center" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Mild pain in stomach</td><td align="center" rowspan="1" colspan="1">1 (2)</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.31</td></tr><tr><td align="left" rowspan="1" colspan="1">Mild body heat</td><td align="center" rowspan="1" colspan="1">1 (2)</td><td align="center" rowspan="1" colspan="1">3 (6)</td><td align="center" rowspan="1" colspan="1">0.30</td></tr></tbody></table></table-wrap></floats-group></article>